“Targeting toll-like receptor 4 (TLR4) and the NLRP3 inflammasome: Novel and emerging therapeutic targets for hyperuricaemia nephropathy” (2023) Biomolecules and Biomedicine, pp. 688–697. doi:10.17305/bb.2023.9838.